Avior Wealth Management LLC Grows Stock Holdings in Cencora, Inc. (NYSE:COR)

Avior Wealth Management LLC boosted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 66.5% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,004 shares of the company's stock after acquiring an additional 2,398 shares during the quarter. Avior Wealth Management LLC's holdings in Cencora were worth $1,351,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Osaic Holdings Inc. purchased a new position in shares of Cencora during the 1st quarter valued at about $9,962,000. Covestor Ltd bought a new position in Cencora during the first quarter valued at approximately $55,000. Ameritas Investment Partners Inc. purchased a new position in shares of Cencora during the first quarter worth approximately $465,000. American International Group Inc. bought a new stake in shares of Cencora in the 1st quarter worth approximately $10,872,000. Finally, InterOcean Capital Group LLC purchased a new stake in shares of Cencora in the 1st quarter valued at $251,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on COR shares. Wells Fargo & Company lifted their price objective on Cencora from $236.00 to $249.00 and gave the stock an "equal weight" rating in a report on Thursday, August 1st. Robert W. Baird increased their price objective on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 21st. Evercore ISI boosted their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Finally, StockNews.com lowered shares of Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $271.20.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 21,509 shares of the company's stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares of the company's stock, valued at approximately $67,223,750.40. This represents a 7.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 15.80% of the stock is owned by corporate insiders.

Cencora Price Performance

NYSE:COR opened at $243.20 on Thursday. The business's 50-day moving average is $232.82 and its 200 day moving average is $231.29. Cencora, Inc. has a 12 month low of $195.83 and a 12 month high of $251.56. The company has a market capitalization of $47.92 billion, a P/E ratio of 32.38, a P/E/G ratio of 1.60 and a beta of 0.44. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.90%. The ex-dividend date of this dividend is Friday, November 15th. This is a positive change from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio is presently 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.